Study population characteristics among 133 324 1-year survivors of invasive breast cancer in the linked SEER-Medicare dataset
| . | History of diabetes . | ||
|---|---|---|---|
| . | No No. = 94 312 (70.7%) . | Yes No. = 39 012 (29.3%) . | Total No. = 133 324 (100.0%) . |
| . | No. (%) . | No. (%) . | No. (%) . |
| Follow-up (years) | |||
| Mean [SD] | 5.5 [4.0] | 4.4 [3.5] | 5.2 [3.9] |
| Median [min, max] | 4.7 [0.003,18] | 3.7 [0.003,17.7] | 4.3 [0.003,18] |
| Age at breast cancer diagnosis (years) | |||
| Mean [SD] | 73.8 [5.01] | 74.6 [4.91] | 74.0 [5.00] |
| Median [min, max] | 73.3 [66.0,83.9] | 74.4 [66.0,83.9] | 73.6 [66.0,83.9] |
| Age range (years) | |||
| 66-69 | 27 372 (29.0) | 8660 (22.2) | 36 032 (27.0) |
| 70-74 | 29 106 (30.9) | 12 195 (31.3) | 41 301 (31.0) |
| 75-79 | 23 735 (25.2) | 11 305 (29.0) | 35 040 (26.3) |
| 80-84 | 14 099 (14.9) | 6852 (17.6) | 20 951 (15.7) |
| Race and ethnicity | |||
| Non-Hispanic American Indian and/or Alaska Native | 224 (0.2) | 179 (0.5) | 403 (0.3) |
| Non-Hispanic Asian | 3081 (3.2) | 2074 (5.3) | 5094 (3.8) |
| Non-Hispanic Black | 4841 (5.1) | 4796 (12.3) | 9637 (7.2) |
| Hispanic (all races) | 3683 (3.9) | 2891 (7.4) | 6574 (4.9) |
| Non-Hispanic Pacific Islander | 251 (0.3) | 188 (0.5) | 439 (0.3) |
| Non-Hispanic White | 82 018 (87.0) | 28 748 (73.7) | 110 766 (83.1) |
| Non-Hispanic Unknown Race | 277 (0.3) | 134 (0.3) | 411 (0.3) |
| Year of first primary breast cancer diagnosis | |||
| 2000-2005 | 36 770 (39.0) | 10 439 (26.8) | 47 209 (35.4) |
| 2006-2011 | 29 386 (31.2) | 13 613 (34.9) | 42 999 (32.3) |
| 2012-2017 | 28 156 (29.9) | 14 960 (38.3) | 43 116 (32.3) |
| First primary breast cancer stage | |||
| I | 53 744 (57.0) | 20 439 (52.4) | 74 183 (55.6) |
| II | 27 502 (29.2) | 12 696 (32.5) | 40 198 (30.2) |
| III | 8232 (8.7) | 3886 (10.0) | 12 118 (9.1) |
| N/A and/or Unknown | 4834 (5.1) | 1991 (5.1) | 6825 (5.1) |
| Hormone receptor status | |||
| Hormone receptor positive | 74 772 (79.3) | 31 297 (80.2) | 106 069 (79.6) |
| Hormone receptor negative | 11 520 (12.2) | 4873 (12.5) | 16 393 (12.3) |
| Borderline | 116 (0.1) | 52 (0.1) | 168 (0.1) |
| Unknown | 7904 (8.4) | 2790 (7.2) | 10 694 (8.0) |
| Primary breast cancer surgery | |||
| No surgery | 3237 (3.4) | 1755 (4.5) | 4992 (3.7) |
| Breast-conserving therapy | 58 601 (62.1) | 23 036 (59.0) | 81 637 (61.2) |
| Unilateral mastectomy | 26 000 (27.6) | 11 571 (29.7) | 37 571 (28.2) |
| Bilateral mastectomy | 2915 (3.1) | 1046 (2.7) | 3961 (3.0) |
| Unknown and/or Missing | 3559 (3.8) | 1604 (4.1) | 5163 (3.9) |
| Radiotherapya | |||
| No and/or Unknown | 34 923 (37.0) | 16 269 (41.7) | 51 192 (38.4) |
| Yes | 59 389 (63.0) | 22 743 (58.3) | 82 132 (61.6) |
| Chemotherapya | |||
| No and/or Unknown | 65 162 (69.1) | 26 613 (68.2) | 91 775 (68.8) |
| Yes | 29 150 (30.9) | 12 399 (31.8) | 41 549 (31.2) |
| Adjusted Charlson score rangesb | |||
| 0 | 69 334 (73.5) | 22 237 (57.0) | 91 571 (68.7) |
| 1-2 | 20 539 (21.8) | 12 922 (33.1) | 33 461 (25.1) |
| 3+ | 2167 (2.3) | 3706 (9.5) | 5873 (4.4) |
| Unknown | 2272 (2.4) | 147 (0.4) | 2419 (1.8) |
| . | History of diabetes . | ||
|---|---|---|---|
| . | No No. = 94 312 (70.7%) . | Yes No. = 39 012 (29.3%) . | Total No. = 133 324 (100.0%) . |
| . | No. (%) . | No. (%) . | No. (%) . |
| Follow-up (years) | |||
| Mean [SD] | 5.5 [4.0] | 4.4 [3.5] | 5.2 [3.9] |
| Median [min, max] | 4.7 [0.003,18] | 3.7 [0.003,17.7] | 4.3 [0.003,18] |
| Age at breast cancer diagnosis (years) | |||
| Mean [SD] | 73.8 [5.01] | 74.6 [4.91] | 74.0 [5.00] |
| Median [min, max] | 73.3 [66.0,83.9] | 74.4 [66.0,83.9] | 73.6 [66.0,83.9] |
| Age range (years) | |||
| 66-69 | 27 372 (29.0) | 8660 (22.2) | 36 032 (27.0) |
| 70-74 | 29 106 (30.9) | 12 195 (31.3) | 41 301 (31.0) |
| 75-79 | 23 735 (25.2) | 11 305 (29.0) | 35 040 (26.3) |
| 80-84 | 14 099 (14.9) | 6852 (17.6) | 20 951 (15.7) |
| Race and ethnicity | |||
| Non-Hispanic American Indian and/or Alaska Native | 224 (0.2) | 179 (0.5) | 403 (0.3) |
| Non-Hispanic Asian | 3081 (3.2) | 2074 (5.3) | 5094 (3.8) |
| Non-Hispanic Black | 4841 (5.1) | 4796 (12.3) | 9637 (7.2) |
| Hispanic (all races) | 3683 (3.9) | 2891 (7.4) | 6574 (4.9) |
| Non-Hispanic Pacific Islander | 251 (0.3) | 188 (0.5) | 439 (0.3) |
| Non-Hispanic White | 82 018 (87.0) | 28 748 (73.7) | 110 766 (83.1) |
| Non-Hispanic Unknown Race | 277 (0.3) | 134 (0.3) | 411 (0.3) |
| Year of first primary breast cancer diagnosis | |||
| 2000-2005 | 36 770 (39.0) | 10 439 (26.8) | 47 209 (35.4) |
| 2006-2011 | 29 386 (31.2) | 13 613 (34.9) | 42 999 (32.3) |
| 2012-2017 | 28 156 (29.9) | 14 960 (38.3) | 43 116 (32.3) |
| First primary breast cancer stage | |||
| I | 53 744 (57.0) | 20 439 (52.4) | 74 183 (55.6) |
| II | 27 502 (29.2) | 12 696 (32.5) | 40 198 (30.2) |
| III | 8232 (8.7) | 3886 (10.0) | 12 118 (9.1) |
| N/A and/or Unknown | 4834 (5.1) | 1991 (5.1) | 6825 (5.1) |
| Hormone receptor status | |||
| Hormone receptor positive | 74 772 (79.3) | 31 297 (80.2) | 106 069 (79.6) |
| Hormone receptor negative | 11 520 (12.2) | 4873 (12.5) | 16 393 (12.3) |
| Borderline | 116 (0.1) | 52 (0.1) | 168 (0.1) |
| Unknown | 7904 (8.4) | 2790 (7.2) | 10 694 (8.0) |
| Primary breast cancer surgery | |||
| No surgery | 3237 (3.4) | 1755 (4.5) | 4992 (3.7) |
| Breast-conserving therapy | 58 601 (62.1) | 23 036 (59.0) | 81 637 (61.2) |
| Unilateral mastectomy | 26 000 (27.6) | 11 571 (29.7) | 37 571 (28.2) |
| Bilateral mastectomy | 2915 (3.1) | 1046 (2.7) | 3961 (3.0) |
| Unknown and/or Missing | 3559 (3.8) | 1604 (4.1) | 5163 (3.9) |
| Radiotherapya | |||
| No and/or Unknown | 34 923 (37.0) | 16 269 (41.7) | 51 192 (38.4) |
| Yes | 59 389 (63.0) | 22 743 (58.3) | 82 132 (61.6) |
| Chemotherapya | |||
| No and/or Unknown | 65 162 (69.1) | 26 613 (68.2) | 91 775 (68.8) |
| Yes | 29 150 (30.9) | 12 399 (31.8) | 41 549 (31.2) |
| Adjusted Charlson score rangesb | |||
| 0 | 69 334 (73.5) | 22 237 (57.0) | 91 571 (68.7) |
| 1-2 | 20 539 (21.8) | 12 922 (33.1) | 33 461 (25.1) |
| 3+ | 2167 (2.3) | 3706 (9.5) | 5873 (4.4) |
| Unknown | 2272 (2.4) | 147 (0.4) | 2419 (1.8) |
Radiotherapy and chemotherapy were classified as “yes” at 1 year after breast cancer diagnosis if there was an indication of treatment receipt in Surveillance Epidemiology and End Results (SEER) or at least 1 Medicare claim within 90 days before breast cancer diagnosis or up to 12 months after first primary breast cancer diagnosis.
Charlson comorbidity scores were adjusted to exclude diabetes and diabetes complications from the final comorbidity core (39).
Study population characteristics among 133 324 1-year survivors of invasive breast cancer in the linked SEER-Medicare dataset
| . | History of diabetes . | ||
|---|---|---|---|
| . | No No. = 94 312 (70.7%) . | Yes No. = 39 012 (29.3%) . | Total No. = 133 324 (100.0%) . |
| . | No. (%) . | No. (%) . | No. (%) . |
| Follow-up (years) | |||
| Mean [SD] | 5.5 [4.0] | 4.4 [3.5] | 5.2 [3.9] |
| Median [min, max] | 4.7 [0.003,18] | 3.7 [0.003,17.7] | 4.3 [0.003,18] |
| Age at breast cancer diagnosis (years) | |||
| Mean [SD] | 73.8 [5.01] | 74.6 [4.91] | 74.0 [5.00] |
| Median [min, max] | 73.3 [66.0,83.9] | 74.4 [66.0,83.9] | 73.6 [66.0,83.9] |
| Age range (years) | |||
| 66-69 | 27 372 (29.0) | 8660 (22.2) | 36 032 (27.0) |
| 70-74 | 29 106 (30.9) | 12 195 (31.3) | 41 301 (31.0) |
| 75-79 | 23 735 (25.2) | 11 305 (29.0) | 35 040 (26.3) |
| 80-84 | 14 099 (14.9) | 6852 (17.6) | 20 951 (15.7) |
| Race and ethnicity | |||
| Non-Hispanic American Indian and/or Alaska Native | 224 (0.2) | 179 (0.5) | 403 (0.3) |
| Non-Hispanic Asian | 3081 (3.2) | 2074 (5.3) | 5094 (3.8) |
| Non-Hispanic Black | 4841 (5.1) | 4796 (12.3) | 9637 (7.2) |
| Hispanic (all races) | 3683 (3.9) | 2891 (7.4) | 6574 (4.9) |
| Non-Hispanic Pacific Islander | 251 (0.3) | 188 (0.5) | 439 (0.3) |
| Non-Hispanic White | 82 018 (87.0) | 28 748 (73.7) | 110 766 (83.1) |
| Non-Hispanic Unknown Race | 277 (0.3) | 134 (0.3) | 411 (0.3) |
| Year of first primary breast cancer diagnosis | |||
| 2000-2005 | 36 770 (39.0) | 10 439 (26.8) | 47 209 (35.4) |
| 2006-2011 | 29 386 (31.2) | 13 613 (34.9) | 42 999 (32.3) |
| 2012-2017 | 28 156 (29.9) | 14 960 (38.3) | 43 116 (32.3) |
| First primary breast cancer stage | |||
| I | 53 744 (57.0) | 20 439 (52.4) | 74 183 (55.6) |
| II | 27 502 (29.2) | 12 696 (32.5) | 40 198 (30.2) |
| III | 8232 (8.7) | 3886 (10.0) | 12 118 (9.1) |
| N/A and/or Unknown | 4834 (5.1) | 1991 (5.1) | 6825 (5.1) |
| Hormone receptor status | |||
| Hormone receptor positive | 74 772 (79.3) | 31 297 (80.2) | 106 069 (79.6) |
| Hormone receptor negative | 11 520 (12.2) | 4873 (12.5) | 16 393 (12.3) |
| Borderline | 116 (0.1) | 52 (0.1) | 168 (0.1) |
| Unknown | 7904 (8.4) | 2790 (7.2) | 10 694 (8.0) |
| Primary breast cancer surgery | |||
| No surgery | 3237 (3.4) | 1755 (4.5) | 4992 (3.7) |
| Breast-conserving therapy | 58 601 (62.1) | 23 036 (59.0) | 81 637 (61.2) |
| Unilateral mastectomy | 26 000 (27.6) | 11 571 (29.7) | 37 571 (28.2) |
| Bilateral mastectomy | 2915 (3.1) | 1046 (2.7) | 3961 (3.0) |
| Unknown and/or Missing | 3559 (3.8) | 1604 (4.1) | 5163 (3.9) |
| Radiotherapya | |||
| No and/or Unknown | 34 923 (37.0) | 16 269 (41.7) | 51 192 (38.4) |
| Yes | 59 389 (63.0) | 22 743 (58.3) | 82 132 (61.6) |
| Chemotherapya | |||
| No and/or Unknown | 65 162 (69.1) | 26 613 (68.2) | 91 775 (68.8) |
| Yes | 29 150 (30.9) | 12 399 (31.8) | 41 549 (31.2) |
| Adjusted Charlson score rangesb | |||
| 0 | 69 334 (73.5) | 22 237 (57.0) | 91 571 (68.7) |
| 1-2 | 20 539 (21.8) | 12 922 (33.1) | 33 461 (25.1) |
| 3+ | 2167 (2.3) | 3706 (9.5) | 5873 (4.4) |
| Unknown | 2272 (2.4) | 147 (0.4) | 2419 (1.8) |
| . | History of diabetes . | ||
|---|---|---|---|
| . | No No. = 94 312 (70.7%) . | Yes No. = 39 012 (29.3%) . | Total No. = 133 324 (100.0%) . |
| . | No. (%) . | No. (%) . | No. (%) . |
| Follow-up (years) | |||
| Mean [SD] | 5.5 [4.0] | 4.4 [3.5] | 5.2 [3.9] |
| Median [min, max] | 4.7 [0.003,18] | 3.7 [0.003,17.7] | 4.3 [0.003,18] |
| Age at breast cancer diagnosis (years) | |||
| Mean [SD] | 73.8 [5.01] | 74.6 [4.91] | 74.0 [5.00] |
| Median [min, max] | 73.3 [66.0,83.9] | 74.4 [66.0,83.9] | 73.6 [66.0,83.9] |
| Age range (years) | |||
| 66-69 | 27 372 (29.0) | 8660 (22.2) | 36 032 (27.0) |
| 70-74 | 29 106 (30.9) | 12 195 (31.3) | 41 301 (31.0) |
| 75-79 | 23 735 (25.2) | 11 305 (29.0) | 35 040 (26.3) |
| 80-84 | 14 099 (14.9) | 6852 (17.6) | 20 951 (15.7) |
| Race and ethnicity | |||
| Non-Hispanic American Indian and/or Alaska Native | 224 (0.2) | 179 (0.5) | 403 (0.3) |
| Non-Hispanic Asian | 3081 (3.2) | 2074 (5.3) | 5094 (3.8) |
| Non-Hispanic Black | 4841 (5.1) | 4796 (12.3) | 9637 (7.2) |
| Hispanic (all races) | 3683 (3.9) | 2891 (7.4) | 6574 (4.9) |
| Non-Hispanic Pacific Islander | 251 (0.3) | 188 (0.5) | 439 (0.3) |
| Non-Hispanic White | 82 018 (87.0) | 28 748 (73.7) | 110 766 (83.1) |
| Non-Hispanic Unknown Race | 277 (0.3) | 134 (0.3) | 411 (0.3) |
| Year of first primary breast cancer diagnosis | |||
| 2000-2005 | 36 770 (39.0) | 10 439 (26.8) | 47 209 (35.4) |
| 2006-2011 | 29 386 (31.2) | 13 613 (34.9) | 42 999 (32.3) |
| 2012-2017 | 28 156 (29.9) | 14 960 (38.3) | 43 116 (32.3) |
| First primary breast cancer stage | |||
| I | 53 744 (57.0) | 20 439 (52.4) | 74 183 (55.6) |
| II | 27 502 (29.2) | 12 696 (32.5) | 40 198 (30.2) |
| III | 8232 (8.7) | 3886 (10.0) | 12 118 (9.1) |
| N/A and/or Unknown | 4834 (5.1) | 1991 (5.1) | 6825 (5.1) |
| Hormone receptor status | |||
| Hormone receptor positive | 74 772 (79.3) | 31 297 (80.2) | 106 069 (79.6) |
| Hormone receptor negative | 11 520 (12.2) | 4873 (12.5) | 16 393 (12.3) |
| Borderline | 116 (0.1) | 52 (0.1) | 168 (0.1) |
| Unknown | 7904 (8.4) | 2790 (7.2) | 10 694 (8.0) |
| Primary breast cancer surgery | |||
| No surgery | 3237 (3.4) | 1755 (4.5) | 4992 (3.7) |
| Breast-conserving therapy | 58 601 (62.1) | 23 036 (59.0) | 81 637 (61.2) |
| Unilateral mastectomy | 26 000 (27.6) | 11 571 (29.7) | 37 571 (28.2) |
| Bilateral mastectomy | 2915 (3.1) | 1046 (2.7) | 3961 (3.0) |
| Unknown and/or Missing | 3559 (3.8) | 1604 (4.1) | 5163 (3.9) |
| Radiotherapya | |||
| No and/or Unknown | 34 923 (37.0) | 16 269 (41.7) | 51 192 (38.4) |
| Yes | 59 389 (63.0) | 22 743 (58.3) | 82 132 (61.6) |
| Chemotherapya | |||
| No and/or Unknown | 65 162 (69.1) | 26 613 (68.2) | 91 775 (68.8) |
| Yes | 29 150 (30.9) | 12 399 (31.8) | 41 549 (31.2) |
| Adjusted Charlson score rangesb | |||
| 0 | 69 334 (73.5) | 22 237 (57.0) | 91 571 (68.7) |
| 1-2 | 20 539 (21.8) | 12 922 (33.1) | 33 461 (25.1) |
| 3+ | 2167 (2.3) | 3706 (9.5) | 5873 (4.4) |
| Unknown | 2272 (2.4) | 147 (0.4) | 2419 (1.8) |
Radiotherapy and chemotherapy were classified as “yes” at 1 year after breast cancer diagnosis if there was an indication of treatment receipt in Surveillance Epidemiology and End Results (SEER) or at least 1 Medicare claim within 90 days before breast cancer diagnosis or up to 12 months after first primary breast cancer diagnosis.
Charlson comorbidity scores were adjusted to exclude diabetes and diabetes complications from the final comorbidity core (39).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
